Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms

Constitutive JAK2 activation in hematopoietic cells by the JAK2V617F mutation recapitulates myeloproliferative neoplasm (MPN) phenotypes in mice, establishing JAK2 inhibition as a potential therapeutic strategy. Although most polycythemia vera patients carry the JAK2V617F mutation, half of those wit...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Quintás-Cardama, Alfonso, Vaddi, Kris, Liu, Phillip, Manshouri, Taghi, Li, Jun, Scherle, Peggy A., Caulder, Eian, Wen, Xiaoming, Li, Yanlong, Waeltz, Paul, Rupar, Mark, Burn, Timothy, Lo, Yvonne, Kelley, Jennifer, Covington, Maryanne, Shepard, Stacey, Rodgers, James D., Haley, Patrick, Kantarjian, Hagop, Fridman, Jordan S., Verstovsek, Srdan
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Society of Hematology 2010
Soggetti:
Myeloid Neoplasia
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3953826/
https://ncbi.nlm.nih.gov/pubmed/20130243
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2009-04-214957
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi